Download PDF
CC BY-NC-ND 4.0 · Avicenna J Med 2017; 07(02): 75-77
DOI: 10.4103/2231-0770.203609
CASE REPORT

Donor-transmitted melanoma after limbal stem cell transplantation

Anas Alsara
Department of Internal Medicine, Michigan State University College of Human Medicine, East Lansing, Michigan, USA
,
Muhammad Rafi
West Michigan Cancer Center, Kalamazoo, Michigan,USA
› Author Affiliations Financial support and sponsorship Nil.
› Further Information
Also available at
  PDF Download Permissions and Reprints

Abstract

Limbal Stem Cells are a unique cell line located at the corneal limbus. They are responsible for regenerating and restoring corneal epithelial layers. Limbal stem cell transplantation is a promising technique that has been used to treat several hereditary and acquired corneal diseases. Cornea tissue lack vascularity. Hence, there were no special restrictions on collecting ocular tissues from donors with a diagnosis of metastatic melanoma. We are reporting a case of a patient who developed an ocular melanoma after she had limbal stem cell transplantation from a donor with history of melanoma. After this case, Eye Bank Association of America updated the donor criteria to exclude donors with any history of melanoma.

Keywords

Donor-transmitted melanoma - limbal stem cell transplant - transplant-related malignancy


Publication History

Article published online:
09 August 2021

© 2017. Syrian American Medical Society. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 Bakhtiari P, Djalilian A. Update on limbal stem cell transplantation. Middle East Afr J Ophthalmol 2010;17:9-14.
  • 2 Campanelli M, Mistò R, Limongelli A, Valente MG, Cuttin MS, D'Amato Tóthová J. A donor cornea with metastatic cells from a cutaneous malignant melanoma. Cornea 2013;32:1613-6.
  • 3 Health Quality Ontario. Limbal stem cell transplantation: An evidence-based analysis. Ont Health Technol Assess Ser 2008;8:1-58.
  • 4 Liang L, Sheha H, Li J, Tseng SC. Limbal stem cell transplantation: New progresses and challenges. Eye (Lond) 2009;23:1946-53.
  • 5 Myron Kauffman H, McBride MA, Cherikh WS, Spain PC, Marks WH, Roza AM. Transplant tumor registry: Donor related malignancies. Transplantation 2002; 74:358-62.
  • 6 Morris-Stiff G, Steel A, Savage P, Devlin J, Griffiths D, Portman B, et al. Transmission of donor melanoma to multiple organ transplant recipients. Am J Transplant 2004;4:444-6.
  • 7 Strauss DC, Thomas JM. Transmission of donor melanoma by organ transplantation. Lancet Oncol 2010;11:790-6.
  • 8 Baker KS, DeFor TE, Burns LJ, Ramsay NK, Neglia JP, Robison LL. New malignancies after blood or marrow stem-cell transplantation in children and adults: Incidence and risk factors. J Clin Oncol 2003;21:1352-8.
  • 9 Zafar SY, Howell DN, Gockerman JP. Malignancy after solid organ transplantation: An overview. Oncologist 2008;13:769-78.
  • 10 Penn I. Evaluation of transplant candidates with pre-existing malignancies. Ann Transplant 1997;2:14-7.
  • 11 Birkeland SA, Storm HH. Risk for tumor and other disease transmission by transplantation: A population-based study of unrecognized malignancies and other diseases in organ donors. Transplantation 2002;74:1409-13.
  • 12 Džambová M, Secníková Z, Jiráková A, Juzlová K, Viklický O, Hošková L, et al. Malignant melanoma in organ transplant recipients: Incidence, outcomes, and management strategies: A review of literature. Dermatol Ther 2016;29:64-8.
  • 13 Penn I. Transmission of cancer from organ donors. Ann Transplant 1997;2:7-12.
  • 14 Kim JY, Djalilian AR, Schwartz GS, Holland EJ. Ocular surface reconstruction: Limbal stem cell transplantation. Ophthalmol Clin North Am 2003;16:67-77.
  • 15 Stephens JK, Everson GT, Elliott CL, Kam I, Wachs M, Haney J, et al. Fatal transfer of malignant melanoma from multiorgan donor to four allograft recipients. Transplantation 2000;70:232-6.
  • 16 Demirci H, McCormick SA, Finger PT. Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: Clinical experience with histopathologic observations. Arch Ophthalmol 2000;118:885-91.
  • 17 Finger PT, Czechonska G, Liarikos S. Topical mitomycin C chemotherapy for conjunctival melanoma and PAM with atypia. Br J Ophthalmol 1998;82:476-9.
  • 18 Schallenberg M, Niederdräing N, Steuhl KP, Meller D. Topical mitomycin C as a therapy of conjunctival tumours. Ophthalmologe 2008; 105:777-84.